United States Biotechnology & Medical Research

X4 Pharmaceuticals Inc (XFOR)

Track

Track

X4 Pharmaceuticals experienced significant selling activity recently, with executives offloading over 350,000 dollars in stock during the last quarter. These transactions followed a positive earnings report in August. Despite the negative price trend over ninety days, leadership remains active in liquidating holdings, reflecting a clear pattern of divestment among key corporate officers.
Ticker: XFOR Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for X4 Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders

Similar companies

View all Biotechnology & Medical Research companies
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Volpone John President Officer
Transaction date
Sale
Price
466.77
Quantity 1,550 -43.4%
Value US$4,154,961
3.3
Craig Adam R Executive Chairman Executive Director
Transaction date
Sale
Price
138.76
Quantity 39,433 -37.4%
Value US$1,552,811
3.3
Adam Craig Executive Chaiman
Transaction date
Proposed sale
Price
128.34
Quantity 33,517
Value US$2,543,182
John Volpone Officer Officer
Transaction date
Proposed sale
Price
4.56
Quantity 24,576
Value US$111,944
3.0
KIRSKE DAVID Chief Financial Officer Officer
Transaction date
Sale
Price
4.26
Quantity 8,543 -4.8%
Value US$36,428
3.0
KIRSKE DAVID Chief Financial Officer Officer
Transaction date
Sale
Price
4.29
Quantity 16,961 -8.8%
Value US$72,820
3.0
David Kirske Officer Officer
Transaction date
Proposed sale
Price
4.29
Quantity 16,961
Value US$72,820
3.3
Craig Adam R Executive Chairman Executive Director
Transaction date
Purchase
Price
2.90
Quantity 86,206 +29.7%
Value US$249,997
Baldry Mark Chief Commercial Officer Officer
Transaction date
Planned purchase
Price
2.48
Quantity 1,032 +4.2%
Value US$2,561
Baldry Mark Chief Commercial Officer Officer
Transaction date
Planned sale
Price
0.45
Quantity 29,159 -23.7%
Value US$13,241
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Planned sale
Price
0.45
Quantity 76,473 -6.6%
Value US$34,719
Arbet-Engels Christophe Chief Medical Officer Officer
Transaction date
Planned sale
Price
0.45
Quantity 11,624 -45.0%
Value US$5,284
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Planned sale
Price
0.45
Quantity 22,258 -4.3%
Value US$10,094
1.5
Mostafa Adam S. Chief Financial Officer Officer
Transaction date
Planned sale
Price
0.45
Quantity 74,773 -100.0%
Value US$33,947
1.5
Ragan Paula Officer Officer
Transaction date
Proposed sale
Price
0.52
Quantity 76,473
Value US$39,766
2.3
DiBiase Mary Officer Officer
Transaction date
Proposed sale
Price
0.52
Quantity 22,258
Value US$11,574
1.9
Taveras Arthur Officer Officer
Transaction date
Proposed sale
Price
0.52
Quantity 24,828
Value US$12,911
Arbet-Engels Christophe Officer Officer
Transaction date
Proposed sale
Price
0.52
Quantity 11,624
Value US$6,044
Baldry Mark Officer Officer
Transaction date
Proposed sale
Price
0.52
Quantity 29,159
Value US$15,163
Baldry Mark Chief Commercial Officer Officer
Transaction date
Planned purchase
Price
0.34
Quantity 13,404 +11.6%
Value US$4,598
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Planned sale
Price
0.39
Quantity 31,897 -3.1%
Value US$12,583
1.5
Ragan Paula Officer Officer
Transaction date
Proposed sale
Price
0.41
Quantity 31,897
Value US$13,078
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Planned sale
Price
0.56
Quantity 31,897 -3.0%
Value US$17,926
1.5
Ragan Paula Officer Officer
Transaction date
Proposed sale
Price
0.56
Quantity 31,897
Value US$17,862
1.5
Mostafa Adam S. Officer Officer
Transaction date
Proposed sale
Price
0.52
Quantity 74,773
Value US$38,882
1.9
Taveras Arthur Chief Scientific Officer Officer
Transaction date
Planned sale
Price
0.56
Quantity 76,920 -16.5%
Value US$43,306
Baldry Mark Chief Commercial Officer Officer
Transaction date
Planned sale
Price
0.58
Quantity 11,127 -18.7%
Value US$6,506
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Planned sale
Price
0.55
Quantity 239,436 -18.5%
Value US$131,522
1.5
Mostafa Adam S. Chief Financial Officer Officer
Transaction date
Planned sale
Price
0.55
Quantity 230,645 -100.0%
Value US$126,901
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Planned sale
Price
0.57
Quantity 67,695 -13.0%
Value US$38,329
2.3
DiBiase Mary Officer Officer
Transaction date
Proposed sale
Price
0.64
Quantity 67,695
Value US$43,095
1.5
Mostafa Adam S. Officer Officer
Transaction date
Proposed sale
Price
0.64
Quantity 230,645
Value US$146,829
1.5
Ragan Paula Officer Officer
Transaction date
Proposed sale
Price
0.64
Quantity 239,436
Value US$152,425
Baldry Mark Officer Officer
Transaction date
Proposed sale
Price
0.64
Quantity 11,127
Value US$7,083
1.9
Taveras Arthur Officer Officer
Transaction date
Proposed sale
Price
0.64
Quantity 76,920
Value US$48,967
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Sale
Price
0.66
Quantity 2,642 -0.9%
Value US$1,738
2.3
DiBiase Mary Officer Officer
Transaction date
Proposed sale
Price
0.65
Quantity 2,642
Value US$1,728
Baldry Mark Chief Commercial Officer Officer
Transaction date
Planned purchase
Price
0.68
Quantity 21,646 +23.0%
Value US$14,654
1.9
Taveras Arthur Officer Officer
Transaction date
Proposed sale
Price
0.90
Quantity 14,235
Value US$12,812
1.5
Mostafa Adam S. Officer Officer
Transaction date
Proposed sale
Price
0.90
Quantity 52,500
Value US$47,250
2.3
DiBiase Mary Officer Officer
Transaction date
Proposed sale
Price
0.90
Quantity 15,409
Value US$13,868
1.5
Ragan Paula Officer Officer
Transaction date
Proposed sale
Price
0.90
Quantity 49,678
Value US$44,710
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Sale
Price
0.88
Quantity 49,678 -6.1%
Value US$43,856
1.5
Mostafa Adam S. Chief Financial Officer Officer
Transaction date
Sale
Price
0.88
Quantity 52,500 -100.0%
Value US$46,347
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Sale
Price
0.88
Quantity 15,409 -5.0%
Value US$13,591
1.9
Taveras Arthur Chief Scientific Officer Officer
Transaction date
Sale
Price
0.88
Quantity 14,235 -5.7%
Value US$12,552
1.9
Taveras Arthur Officer Officer
Transaction date
Proposed sale
Price
0.97
Quantity 787
Value US$763
1.5
Mostafa Adam S. Officer Officer
Transaction date
Proposed sale
Price
0.97
Quantity 27,721
Value US$26,889
2.3
DiBiase Mary Officer Officer
Transaction date
Proposed sale
Price
0.97
Quantity 3,683
Value US$3,573
1.5
Ragan Paula Officer Officer
Transaction date
Proposed sale
Price
0.97
Quantity 21,695
Value US$21,044
1.5
Mostafa Adam S. Chief Financial Officer Officer
Transaction date
Planned sale
Price
1.01
Quantity 27,721 -34.6%
Value US$27,973
1.9
Taveras Arthur Chief Scientific Officer Officer
Transaction date
Sale
Price
1.01
Quantity 787 -0.3%
Value US$793
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Sale
Price
1.01
Quantity 3,683 -1.2%
Value US$3,709
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Planned sale
Price
1.01
Quantity 21,695 -2.6%
Value US$21,892
1.5
Ragan Paula Officer Officer
Transaction date
Proposed sale
Price
0.80
Quantity 39,906
Value US$32,096
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Planned sale
Price
0.90
Quantity 39,906 -4.6%
Value US$35,915
1.9
Taveras Arthur Chief Scientific Officer Officer
Transaction date
Planned sale
Price
0.73
Quantity 67,695 -21.4%
Value US$49,417
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Planned sale
Price
0.73
Quantity 67,695 -17.9%
Value US$49,417
1.5
Mostafa Adam S. Chief Financial Officer Officer
Transaction date
Planned sale
Price
0.73
Quantity 230,645 -74.2%
Value US$168,371
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Planned sale
Price
0.73
Quantity 199,531 -18.5%
Value US$145,658
Baldry Mark Chief Commercial Officer Officer
Transaction date
Planned sale
Price
0.73
Quantity 10,257 -29.4%
Value US$7,488
1.5
Ragan Paula Officer Officer
Transaction date
Proposed sale
Price
0.79
Quantity 199,531
Value US$157,848
2.3
DiBiase Mary Officer Officer
Transaction date
Proposed sale
Price
0.79
Quantity 67,695
Value US$53,553
1.9
Taveras Arthur Affiliate
Transaction date
Proposed sale
Price
0.79
Quantity 67,695
Value US$53,553
Baldry Mark Officer Officer
Transaction date
Proposed sale
Price
0.79
Quantity 10,257
Value US$8,144
1.5
Mostafa Adam S. Officer Officer
Transaction date
Proposed sale
Price
0.79
Quantity 230,645
Value US$182,463
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Planned sale
Price
1.25
Quantity 2,642 -1.8%
Value US$3,300
2.3
DiBiase Mary Officer Officer
Transaction date
Proposed sale
Price
1.24
Quantity 2,642
Value US$3,276
0.6
WYZGA MICHAEL S Non-Executive Director
Transaction date
Purchase
Price
1.20
Quantity 25,000 +48.4%
Value US$29,875
2.3
Stewart Murray Interim Chief Medical Officer Executive Director
Transaction date
Sale
Price
1.06
Quantity 130,056 -47.0%
Value US$137,859
1.5
Mostafa Adam S. Chief Financial Officer Officer
Transaction date
Planned sale
Price
1.89
Quantity 2,641 -3.2%
Value US$4,991
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Planned sale
Price
1.89
Quantity 464 -0.3%
Value US$877
1.5
Ragan Paula President and CEO Executive Director
Transaction date
Planned sale
Price
1.92
Quantity 6,724 -1.2%
Value US$12,910
1.5
Mostafa Adam S. Chief Financial Officer Officer
Transaction date
Planned sale
Price
1.93
Quantity 5,417 -6.1%
Value US$10,455
2.3
DiBiase Mary Chief Operating Officer Officer
Transaction date
Planned sale
Price
1.93
Quantity 857 -0.6%
Value US$1,654
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-13 2026-08-12 S Sale
Volpone John

President

Officer
1,550 -43.4%
466.77
US$4,154,961 		1,550 -43.4% 466.77 US$4,154,961
2026-08-13 2026-08-12 S Sale
3.3
Craig Adam R

Executive Chairman

Executive Director
39,433 -37.4%
138.76
US$1,552,811 		39,433 -37.4% 138.76 US$1,552,811
2026-08-13 2026-08-12 PrS Proposed sale
3.3
Adam Craig

Executive Chaiman
33,517
128.34
US$2,543,182 		33,517 128.34 US$2,543,182
2026-08-13 2026-08-12 PrS Proposed sale
John Volpone

Officer

Officer
24,576
4.56
US$111,944 		24,576 4.56 US$111,944
2026-07-01 2026-06-30 S Sale
3.0
KIRSKE DAVID

Chief Financial Officer

Officer
8,543 -4.8%
4.26
US$36,428 		8,543 -4.8% 4.26 US$36,428
2026-05-13 2026-05-12 S Sale
3.0
KIRSKE DAVID

Chief Financial Officer

Officer
16,961 -8.8%
4.29
US$72,820 		16,961 -8.8% 4.29 US$72,820
2026-05-12 2026-05-12 PrS Proposed sale
3.0
David Kirske

Officer

Officer
16,961
4.29
US$72,820 		16,961 4.29 US$72,820
2025-10-27 2025-10-23 B Purchase
3.3
Craig Adam R

Executive Chairman

Executive Director
86,206 +29.7%
2.90
US$249,997 		86,206 +29.7% 2.90 US$249,997
2025-05-20 2025-05-16 PP Planned purchase
Baldry Mark

Chief Commercial Officer

Officer
1,032 +4.2%
2.48
US$2,561 		1,032 +4.2% 2.48 US$2,561
2025-01-27 2025-01-24 PlS Planned sale
Baldry Mark

Chief Commercial Officer

Officer
29,159 -23.7%
0.45
US$13,241 		29,159 -23.7% 0.45 US$13,241
2025-01-27 2025-01-24 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
76,473 -6.6%
0.45
US$34,719 		76,473 -6.6% 0.45 US$34,719
2025-01-27 2025-01-24 PlS Planned sale
Arbet-Engels Christophe

Chief Medical Officer

Officer
11,624 -45.0%
0.45
US$5,284 		11,624 -45.0% 0.45 US$5,284
2025-01-27 2025-01-24 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
22,258 -4.3%
0.45
US$10,094 		22,258 -4.3% 0.45 US$10,094
2025-01-27 2025-01-24 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
74,773 -100.0%
0.45
US$33,947 		74,773 -100.0% 0.45 US$33,947
2025-01-24 2025-01-24 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
76,473
0.52
US$39,766 		76,473 0.52 US$39,766
2025-01-24 2025-01-24 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
22,258
0.52
US$11,574 		22,258 0.52 US$11,574
2025-01-24 2025-01-24 PrS Proposed sale
1.9
Taveras Arthur

Officer

Officer
24,828
0.52
US$12,911 		24,828 0.52 US$12,911
2025-01-24 2025-01-24 PrS Proposed sale
Arbet-Engels Christophe

Officer

Officer
11,624
0.52
US$6,044 		11,624 0.52 US$6,044
2025-01-24 2025-01-24 PrS Proposed sale
Baldry Mark

Officer

Officer
29,159
0.52
US$15,163 		29,159 0.52 US$15,163
2025-02-14 2024-11-15 PP Planned purchase Baldry Mark

Chief Commercial Officer

Officer
13,404 +11.6%
0.34
US$4,598 		13,404 +11.6% 0.34 US$4,598
2024-11-19 2024-11-15 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
31,897 -3.1%
0.39
US$12,583 		31,897 -3.1% 0.39 US$12,583
2024-11-15 2024-11-15 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
31,897
0.41
US$13,078 		31,897 0.41 US$13,078
2024-10-16 2024-10-15 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
31,897 -3.0%
0.56
US$17,926 		31,897 -3.0% 0.56 US$17,926
2024-10-15 2024-10-15 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
31,897
0.56
US$17,862 		31,897 0.56 US$17,862
2025-01-24 2024-10-07 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
74,773
0.52
US$38,882 		74,773 0.52 US$38,882
2024-10-08 2024-10-07 PlS Planned sale
1.9
Taveras Arthur

Chief Scientific Officer

Officer
76,920 -16.5%
0.56
US$43,306 		76,920 -16.5% 0.56 US$43,306
2024-10-08 2024-10-07 PlS Planned sale
Baldry Mark

Chief Commercial Officer

Officer
11,127 -18.7%
0.58
US$6,506 		11,127 -18.7% 0.58 US$6,506
2024-10-08 2024-10-07 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
239,436 -18.5%
0.55
US$131,522 		239,436 -18.5% 0.55 US$131,522
2024-10-08 2024-10-07 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
230,645 -100.0%
0.55
US$126,901 		230,645 -100.0% 0.55 US$126,901
2024-10-08 2024-10-07 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
67,695 -13.0%
0.57
US$38,329 		67,695 -13.0% 0.57 US$38,329
2024-10-07 2024-10-07 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
67,695
0.64
US$43,095 		67,695 0.64 US$43,095
2024-10-07 2024-10-07 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
230,645
0.64
US$146,829 		230,645 0.64 US$146,829
2024-10-07 2024-10-07 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
239,436
0.64
US$152,425 		239,436 0.64 US$152,425
2024-10-07 2024-10-07 PrS Proposed sale
Baldry Mark

Officer

Officer
11,127
0.64
US$7,083 		11,127 0.64 US$7,083
2024-10-07 2024-10-07 PrS Proposed sale
1.9
Taveras Arthur

Officer

Officer
76,920
0.64
US$48,967 		76,920 0.64 US$48,967
2024-09-11 2024-09-09 S Sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
2,642 -0.9%
0.66
US$1,738 		2,642 -0.9% 0.66 US$1,738
2024-09-09 2024-09-09 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
2,642
0.65
US$1,728 		2,642 0.65 US$1,728
2025-02-14 2024-05-17 PP Planned purchase Baldry Mark

Chief Commercial Officer

Officer
21,646 +23.0%
0.68
US$14,654 		21,646 +23.0% 0.68 US$14,654
2024-03-11 2024-03-11 PrS Proposed sale
1.9
Taveras Arthur

Officer

Officer
14,235
0.90
US$12,812 		14,235 0.90 US$12,812
2024-03-11 2024-03-11 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
52,500
0.90
US$47,250 		52,500 0.90 US$47,250
2024-03-11 2024-03-11 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
15,409
0.90
US$13,868 		15,409 0.90 US$13,868
2024-03-11 2024-03-11 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
49,678
0.90
US$44,710 		49,678 0.90 US$44,710
2024-03-11 2024-03-11 S Sale
1.5
Ragan Paula

President and CEO

Executive Director
49,678 -6.1%
0.88
US$43,856 		49,678 -6.1% 0.88 US$43,856
2024-03-11 2024-03-11 S Sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
52,500 -100.0%
0.88
US$46,347 		52,500 -100.0% 0.88 US$46,347
2024-03-11 2024-03-11 S Sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
15,409 -5.0%
0.88
US$13,591 		15,409 -5.0% 0.88 US$13,591
2024-03-11 2024-03-11 S Sale
1.9
Taveras Arthur

Chief Scientific Officer

Officer
14,235 -5.7%
0.88
US$12,552 		14,235 -5.7% 0.88 US$12,552
2024-02-12 2024-02-12 PrS Proposed sale
1.9
Taveras Arthur

Officer

Officer
787
0.97
US$763 		787 0.97 US$763
2024-02-12 2024-02-12 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
27,721
0.97
US$26,889 		27,721 0.97 US$26,889
2024-02-12 2024-02-12 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
3,683
0.97
US$3,573 		3,683 0.97 US$3,573
2024-02-12 2024-02-12 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
21,695
0.97
US$21,044 		21,695 0.97 US$21,044
2024-02-12 2024-02-12 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
27,721 -34.6%
1.01
US$27,973 		27,721 -34.6% 1.01 US$27,973
2024-02-12 2024-02-12 S Sale
1.9
Taveras Arthur

Chief Scientific Officer

Officer
787 -0.3%
1.01
US$793 		787 -0.3% 1.01 US$793
2024-02-12 2024-02-12 S Sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
3,683 -1.2%
1.01
US$3,709 		3,683 -1.2% 1.01 US$3,709
2024-02-12 2024-02-12 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
21,695 -2.6%
1.01
US$21,892 		21,695 -2.6% 1.01 US$21,892
2023-11-03 2023-11-03 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
39,906
0.80
US$32,096 		39,906 0.80 US$32,096
2023-11-03 2023-11-03 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
39,906 -4.6%
0.90
US$35,915 		39,906 -4.6% 0.90 US$35,915
2023-11-03 2023-11-01 PlS Planned sale
1.9
Taveras Arthur

Chief Scientific Officer

Officer
67,695 -21.4%
0.73
US$49,417 		67,695 -21.4% 0.73 US$49,417
2023-11-03 2023-11-01 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
67,695 -17.9%
0.73
US$49,417 		67,695 -17.9% 0.73 US$49,417
2023-11-03 2023-11-01 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
230,645 -74.2%
0.73
US$168,371 		230,645 -74.2% 0.73 US$168,371
2023-11-03 2023-11-01 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
199,531 -18.5%
0.73
US$145,658 		199,531 -18.5% 0.73 US$145,658
2023-11-03 2023-11-01 PlS Planned sale
Baldry Mark

Chief Commercial Officer

Officer
10,257 -29.4%
0.73
US$7,488 		10,257 -29.4% 0.73 US$7,488
2023-11-01 2023-11-01 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
199,531
0.79
US$157,848 		199,531 0.79 US$157,848
2023-11-01 2023-11-01 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
67,695
0.79
US$53,553 		67,695 0.79 US$53,553
2023-11-01 2023-11-01 PrS Proposed sale
1.9
Taveras Arthur

Affiliate
67,695
0.79
US$53,553 		67,695 0.79 US$53,553
2023-11-01 2023-11-01 PrS Proposed sale
Baldry Mark

Officer

Officer
10,257
0.79
US$8,144 		10,257 0.79 US$8,144
2023-11-01 2023-11-01 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
230,645
0.79
US$182,463 		230,645 0.79 US$182,463
2023-09-12 2023-09-08 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
2,642 -1.8%
1.25
US$3,300 		2,642 -1.8% 1.25 US$3,300
2023-09-08 2023-09-08 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
2,642
1.24
US$3,276 		2,642 1.24 US$3,276
2023-08-22 2023-08-18 B Purchase
0.6
WYZGA MICHAEL S
Non-Executive Director
25,000 +48.4%
1.20
US$29,875 		25,000 +48.4% 1.20 US$29,875
2023-08-11 2023-08-10 S Sale
2.3
Stewart Murray

Interim Chief Medical Officer

Executive Director
130,056 -47.0%
1.06
US$137,859 		130,056 -47.0% 1.06 US$137,859
2023-07-05 2023-06-30 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
2,641 -3.2%
1.89
US$4,991 		2,641 -3.2% 1.89 US$4,991
2023-07-05 2023-06-30 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
464 -0.3%
1.89
US$877 		464 -0.3% 1.89 US$877
2023-06-26 2023-06-23 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
6,724 -1.2%
1.92
US$12,910 		6,724 -1.2% 1.92 US$12,910
2023-06-26 2023-06-23 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
5,417 -6.1%
1.93
US$10,455 		5,417 -6.1% 1.93 US$10,455
2023-06-26 2023-06-23 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
857 -0.6%
1.93
US$1,654 		857 -0.6% 1.93 US$1,654
Explore more

More insider trading research around X4 Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America